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Objective: To assess whether children at-risk for celiac disease should be screened systematically 
by comparing their baseline and follow-up characteristics to patients detected because of clinical 
suspicion. 
Study design: Altogether 504 celiac disease children were divided into screen-detected (n=145) 
and clinically detected cohorts (n=359) and the groups underwent comparisons of clinical, 
serological and histological characteristics and laboratory values. Further, follow-up data regarding 
adherence and response to gluten-free diet were compared. Subgroup analyses were made between 
asymptomatic and symptomatic screen-detected patients. 
Results: Altogether 51.8% of screen-detected patients also had symptoms at diagnosis, although 
these were milder than in clinically detected children (p<0.001). Anemia (7.1% vs 22.9%, p<0.001) 
and poor growth (15.7% vs 36.9%, p<0.001) were more common and hemoglobin (126 g/l vs 124 
g/l, p=0.008) and albumin (41.0 g/l vs 38.0 g/l, p=0.016) lower in clinically detected patients, but 
there were no differences in serology or histology between the groups. Screen-detected children 
evinced better dietary adherence (91.2% vs 83.2%, p=0.047), and the groups showed equal clinical 
response (97.5% vs 96.2%, p=0.766) to the gluten-free diet. In subgroup analysis among screen-
detected children, asymptomatic patients were older than symptomatic (9.0 yr vs 5.8 yr, p=0.007), 
but the groups were comparable in other variables. 
Conclusion: More than half of the screen-detected celiac disease patients here had symptoms 
unrecognized at diagnosis. Further, they had severity of histological damage, antibody levels, 
dietary adherence and response to treatment comparable to those detected on clinical basis. The 




During the past few decades, celiac disease has become a major public health issue with an 
estimated prevalence of 1–3% in many Western and Asian countries.1–3 However, due to the 
plethora of unspecific gastrointestinal and extra-intestinal symptoms involved, the great majority of 
affected children remain unrecognized.1,2 Since screening for the disease is simple by modern 
antibody tests, it has been suggested that for increased diagnostic efficiency we should screen either 
known at-risk groups4–6 or even the whole population.7 However, although celiac disease fulfils 
several WHO criteria for screening, the overall benefits of this approach remain controversial.8,9 In 
particular, it remains unclear how well often mildly symptomatic or apparently asymptomatic 
screen-detected patients adhere to the demanding and socially restrictive gluten-free diet.6,10–17 
Although untreated celiac disease is known to predispose to severe complications and incur 
incremental use of health care services and medicines in symptomatic patients,9,18,19 it is obscure 
whether this also applies to screen-detected individuals, especially as it is possible that they have 
less severe histological damage20 and subsequently better long-term outcome. Then again, 
complications such as poor growth, dental enamel defects and low bone mass have been observed 
even in otherwise asymptomatic children with celiac disease, and these maladies may remain 
permanent if left untreated.21–23  
In order to further elucidate the potential benefits and detriments of celiac disease 
screening, we compared clinical, serological and histological features and follow-up results between 
children detected in the course of risk-group screening and those found due to clinical suspicion.  
 
Methods 
Patients and study design 
The study was conducted at the Tampere Center for Child Health Research, University of Tampere 
and Tampere University Hospital, and at the Department of Pediatrics, Tampere University 
Hospital. Patient data were collected from our continuously updated research database, which 
contains medical information on children diagnosed with celiac disease from the late 1960s to the 
present. Lacking or incomplete patient information has been supplemented with personal or 
telephone interviews by an experienced physician or study nurse. From the year 2012 onwards most 
of the database patients have participated in a prospective study enrolment. In order to increase the 
integrity of the results, only children diagnosed from the year 2000 onwards were included. 
Exclusion criteria were age ≥18 years, unclear diagnosis of celiac disease and lack of data regarding 
the initial clinical presentation. Altogether 504 children with biopsy-proven celiac disease 
comprised the final study cohort.  
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The following celiac disease-related information was collected on each child at the time 
of the diagnosis (below in detail): clinical characteristics, severity of histological damage, celiac 
disease serology and a variety of other laboratory parameters, and presence of celiac disease in the 
family. In addition, follow-up data regarding adherence and clinical and serological response to the 
gluten-free diet were recorded. After data assembly, the results were compared between children 
detected by screening and those found on the grounds of clinical suspicion. For the corresponding 
subgroup analysis, screen-detected children were further divided into asymptomatic and 
symptomatic patients.  
The Pediatric Clinic of Tampere University Hospital and the Ethics Committee of the 
Pirkanmaa Hospital District, Tampere, Finland, approved data collection from medical records and 
supplementary patient interviews. Written informed consent was obtained from all subjects and/or 




Screen-detected patients included at-risk children such as those with celiac disease in relatives (first 
degree or more distant) or type 1 diabetes (T1DM) or autoimmune thyroidal disease as a 
comorbidity. Some patients were screened for celiac disease because of attendance in a follow-up 
study due to increased genetic risk for T1DM. Clinically detected children were diagnosed on the 
basis of gastrointestinal or extra-intestinal symptoms or findings, including diarrhea, abdominal 
pain, constipation, arthralgia, dermatitis herpetiformis, anemia and poor growth. Severity of 
symptoms was classified as: 1) no symptoms; 2) mild symptoms (occasionally disturbing minor 
symptoms); 3) moderate symptoms (more frequent and distracting symptoms); and 4) severe 
symptoms (distracting symptoms causing e.g. recurrent nighttime awakenings and school absence). 
Anemia and poor growth were considered as findings or complications of celiac disease and were 
thus not included to the classification of symptoms. Height and weight at the diagnosis were noted 
and expressed in age- and gender-dependent standard deviation (SD) units. Poor growth was 
defined based on abnormalities in expected height and growth velocity as described elsewhere.23,24 
Body mass index was calculated as weight/height2 (kg/m2). 
 
Small-bowel mucosal damage and laboratory parameters  
At least four distal duodenal mucosal samples were taken upon gastrointestinal endoscopy in all 
children with celiac disease suspicion. From the year 2012 onwards, the samples have also been 
systematically obtained from the duodenal bulb.25 The biopsies were referred to the hospital 
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pathology unit, where the severity of mucosal damage was assessed from several well-orientated 
biopsy sections26 and further categorized as mild (Marsh IIIa), moderate (Marsh IIIb) or total 
villous atrophy (Marsh IIIc). 
Transglutaminase 2 antibodies (TG2ab) were measured at the local hospital laboratory 
by either automatized EliA assay (Phadia AB, Uppsala, Sweden), or before the year 2011 by 
conventional ELISA (Phadia). In our laboratory, values 7 U/l or higher for TG2ab are considered 
positive and 120 U/l is the highest reported value. Serum endomysial antibodies (EmA) were 
measured in our research center by indirect immunofluorescence as previously described.20,27 A 
dilution of 1:≥5 for EmA was considered positive and further diluted up to 1:4000 or until negative.  
Results of the following laboratory tests were collected on each child when available: 
blood hemoglobin (Hb) (g/l), erythrocyte mean corpuscular volume (MCV) (reference value (Rf) 
73–95 fl), plasma albumin (Rf 36–48 g/l), plasma transferrin receptor (TfR) (age- and sex-matched 
Rf),28 plasma ferritin (Rf >20 µg/l), plasma alanine aminotransferase (ALT) (Rf ≤30  U/l)29 and 
plasma thyroid-stimulating hormone (TSH) (Rf 0.27–4.2 mU/l). Anemia was defined as a Hb value 
below the age- and sex-matched reference.30 For consistency, only laboratory values taken at the 
time of diagnostic evaluations were accepted for the baseline comparisons. Values other than Hb 
started to be taken systematically only during the latter part of the study period. 
 
Follow-up investigations 
All children initiated a gluten-free diet shortly after the diagnosis under the supervision of a 
qualified dietitian. Adherence to the diet was assessed during each follow-up visit based on self-
reported gluten avoidance and results of serology, and categorized into strict diet, occasional lapses 
and no diet. Clinical and serological response to the dietary treatment was also evaluated and 
classified as: 1) good response (disappearance of symptoms and normalized or markedly decreased 
celiac antibody levels); or 2) no response (persistent symptoms and/or antibody positivity). Routine 
follow-up visits in our clinical practice took place approximately 3–6 and 10–12 months after the 
celiac disease diagnosis. Further, 120 of the children were supplementary interviewed after a 
median of 4 years from the diagnosis. Results of follow-up serology were analyzed in detail by 
comparing the baseline TG2ab values to those measured after a median of 13 (range 6–24) months 
on a gluten-free diet. 
 
Statistics 
Categorized variables are reported as percentage distributions and numeric variables as medians 
with quartiles. Chi-square test or Fisher’s exact test was used to compare categorized variables and 
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Mann-Whitney U test with numeric variables. Binary logistic regression was used to adjust age 
differences between the groups. A P value <0.05 was considered significant. Analyses were 
performed with SPSS version 22 (IBM Corp., Armonk, NY). 
  
Results 
Altogether 145 (28.8%) of the children were detected by screening and 359 (71.2%) on clinical 
basis (Table 1). The main presentation was gastrointestinal in 68.0% and extra-intestinal in 32.0% 
of the patients detected due to symptoms. There were no differences between screen- and clinically 
detected children in age or gender, but celiac disease in first-degree relatives and concomitant 
T1DM were more common among the screen-detected children (Table 1) these also being the 
primary reasons for screening. Clinically detected patients had more anemia and poor growth, but 
these disorders were also seen in a substantial proportion of those found by screening (Table 1).  
As many as 51.8% of the screen-detected children also reported symptoms 
unrecognized at diagnosis, even if less severe than in patients diagnosed in clinical practice (Fig. 
1A–B; online only). In detailed analysis, diarrhea or loose stools were more common among 
clinically detected patients, but otherwise the groups did not differ in the distribution of symptoms 
(Table 2; online only). There were no significant differences between the study groups in 
anthropometric measurements (Table 3) or severity of histological damage (Fig. 1C; online only). 
In three screen-detected and in ten clinically detected children the celiac disease diagnosis was 
based on lesion in duodenal bulb only (p=1.000). The median blood Hb and serum albumin were 
slightly lower among clinically detected subjects (Table 3), but except for anemia, the prevalence of 
abnormal laboratory values did not differ between the groups (clinically vs screen-detected): low 
albumin 23.0% vs 10.5%, p=0.343; MCV 10.6% vs 13.4%, p=0.515; and ferritin 20.5% vs 20.0% 
p=0.958; and increased TfR 31.3% vs 22.2%, p=0.451; ALT 15.6% vs 16.0%, p=1.000; and TSH 
14.2% vs 7.3%, p=0.251, respectively. 
Adherence to a gluten-free diet was better among the screen-detected children (Fig. 1D; 
online only). However, there was no significant association between the presence of strict 
adherence and celiac disease in the family (celiac disease 81.3% vs no disease 90.4%, p=0.060) or 
concomitant type 1 diabetes in the child (T1DM 85.8% vs no T1DM 84.6%, p=0.835). The clinical 
and serologic response were equally good in both groups (97.5% vs 96.2%, p=0.766). Similarly, 
while on diet serum TG2abs decreased in all but two screen-detected and in all clinically detected 
patients (Fig. 2); on later follow-up the antibodies declined even in the two cases with no initial 
response (data not shown). The median time on a gluten-free diet before the follow-up TG2ab 
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measurement was comparable between the screen-detected and clinically detected children (12.0 vs 
11.0 months, p=0.090). 
Among the screen-detected patients, symptomatic children were significantly younger 
and had higher EmA and lower median Hb compared with those asymptomatic upon crude analysis, 
but the differences in EmA and Hb were no longer significant when adjusted for age (Table 4). 
There were no differences between the subgroups in gender, growth parameters or presence of 
anemia, concomitant T1DM and celiac disease in relatives (Table 4) or prevalence of abnormal 
laboratory values (data not shown). Further, the screen-detected groups were comparable in severity 
of histological damage and dietary adherence (Fig. 3; online only).  
There was no association between EmA or TG2ab levels and the severity of villous 
atrophy in screen-detected patients (median EmA titers Marsh IIIa=1:200, IIIb=1:500, IIIc=1:500, 
p=0.164; TG2ab levels 86.0 U/l, 114.0 U/l and 113.0 U/l, respectively, p=0.318), whereas the 
association was seen when evaluated in the whole group (EmA 1:200, 1:500 and 1:1000, p<0.001; 
TG2ab 72.0 U/l, 120.0 U/l, 120.0 U/l, p<0.001). 
 
Discussion 
The present study demonstrated that even screen-detected children very often suffer from 
unrecognized clinical symptoms and signs of celiac disease before diagnosis. Further, 
notwithstanding the different diagnostic approach, these patients are comparable to those found on 
clinical basis in respect of histological and serological markers of disease severity, and show even 
better adherence and response to the gluten-free diet. Our findings support active screening of celiac 
disease among at-risk children. However, benefits of screening on health outcomes in unselected 
population remain obscure. 
Over half of the screen-detected children here reported gluten-responsive symptoms, 
which had neither led to a doctor visit nor been recognized as celiac disease in clinical practice. In 
line with this, other recent studies conducted among screened children and adults have shown up to 
34–84% of such patients to suffer from symptoms unrecognized at the time of the celiac disease 
diagnosis.11,15,31,32 These findings demonstrate that symptom-based case finding is too inefficient to 
detect a large part of even children with classical gastrointestinal presentation, let alone those who 
present with atypical or subtle symptoms. What is more, most of the above mentioned pediatric 
screening studies have been conducted in Finland and other Nordic countries, where the disease is 
fairly well-known among pediatricians and primary care physicians,15,32 and in many other 
countries the situation might be even poorer. For example, in the USA only 17% of all celiac 
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disease patients were aware of their disorder before population screening,33 and such 
underdiagnosing has also been observed in New Zealand and Australia.34 
Besides unrecognized symptoms, many of the screen-detected children here suffered 
from poor growth and anemia, which were not recognized as a sign of celiac disease before the 
screening. There has been debate as to whether the risk of long-term complications is similar among 
screen- and clinically detected patients,9,18 but data actually comparing these two groups are limited. 
Previously Korponay-Szabó and colleagues reported a high prevalence of 22% for anemia and 31% 
for poor growth in a population-based cohort of screen-detected schoolchildren in Hungary.35 We 
have also shown these prominent complications to be present in otherwise asymptomatic 
patients,23,36 and there is some evidence that the introduction of a gluten-free diet can improve poor 
growth and hemoglobin values also in screen-detected children.37 Other possible complications 
which have been observed regardless of the clinical presentation of celiac disease are for instance 
low bone mineral density, dental enamel defects and elevated transaminases.21,22,29,38 
Further supporting the presence of advanced disease and risk of complications, the 
screen-detected children here had levels of celiac disease autoantibodies and severity of villous 
atrophy similar to those detected on clinical basis. It is possible that, despite equal severity of 
histological injury, the clinically detected group had longer length of small intestinal injury, which 
may explain their apparent gastrointestinal symptoms.39 However, the current evidence in adults 
does not support this hypothesis.40 Earlier studies have yielded inconsistent results on the 
correlation between clinical picture and histological findings in celiac disease.20,41–43 Apart from 
differences in study designs these discrepancies might be at least partly explained by differences in 
clinical presentation of the disease between countries. During recent decades, studies from many 
developed countries have reported that the severity of celiac disease is becoming milder even in the 
subgroup of patients suffering from classical gastrointestinal symptoms,44,45 which may contribute 
to the increasing similarity between clinically and screen-detected children. Nevertheless, in favor 
of early diagnosis and treatment, more than half of the children in both groups here already had 
either moderate or total villous atrophy at diagnosis. 
With a view to the reasonableness of screening, we consider it of prime importance that 
the compliance to gluten-free diet be comparable among screen- and symptom-detected children. 
Further verifying their excellent dietary adherence, the study groups showed equal clinical and 
serological response to the diet. Even if not all evinced complete normalization of antibodies during 
follow-up, a similar slow response in some celiac disease patients has also been noted 
elsewhere.12,37 The present study confirmed the results of our previous survey-based study, in which 
the diagnostic approach also had no effect on dietary adherence,15 and similar observations have 
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recently been reported from the Netherlands and Sweden.12,14 In contrast, in an earlier Italian study 
only 23% of screen-detected adolescents had satisfactory adherence to a gluten-free diet five years 
after the celiac disease diagnosis.10 It must, however, be emphasized that these patients were found 
by population-based mass-screening. Additional explanations for variable adherence might be 
differences in the availability and cost of gluten-free products, these being in many countries 
difficult to find in basic budget markets, and in awareness of celiac disease for example in 
restaurants.46 Moreover, in Finland and some other countries governments financially support every 
child with confirmed celiac disease,47 although this was the case also in the above-mentioned Italian 
study showing poor adherence.10 Other factors likely affecting dietary adherence could be the 
intensity and organization of follow-up, the possibility to meet a dietician, the presence of 
comorbidities, and celiac disease in other family members.13,16,48 However, we found no association 
between the adherence and presence of concomitant type 1 diabetes in the child or celiac disease in 
the family. In any case, our results demonstrate that excellent adherence to the gluten-free diet is 
also attainable in screen-detected celiac disease patients diagnosed and followed in a well-organized 
clinical practice. 
Even if the benefits of the gluten-free diet in the present and some earlier studies favor 
screening and active treatment of celiac disease,6,15,17,31 there is reason for caution. Besides the 
social restrictions and economic burden,6,11,49 it is possible that the often nutritionally unbalanced 
diet predisposes some patients to suboptimal intake of vitamins and trace elements and to 
obesity.50,51 Further, despite the promising short-term results, there is a risk that dietary adherence 
declines later in adolescence and adulthood, when follow-up usually becomes less frequent and 
responsibility for daily treatment shifts from the parents to the patients themselves. This issue has 
been scantily studied, but a few years ago Van Koppen and colleagues reported good adherence and 
improved health in a majority of screen-detected children even 10 years after diagnosis.14 In 
contrast, in an earlier study by O’Leary and associated only 50% of the celiac disease patients 
diagnosed in childhood remained on a strict gluten-free diet after a median of 28 years’ follow-up.52 
In adults, dietary lapses have been a problem particularly in asymptomatic patients,11 whereas this 
was not the case in the present study. More studies evaluating dietary adherence and the benefits of 
a gluten-free diet in the long term in screen-detected children are evidently required. 
The main strengths of the present study were the large cohort of celiac disease patients 
diagnosed on uniform nationwide criteria, and the wide array of serological and histological 
variables available. In addition, follow-up data regarding adherence and clinical and serological 
response to the gluten-free diet were documented on the majority of the children. The main 
limitations include the mostly retrospective design, lack of systematic collection of laboratory 
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parameters other than serology during the whole study period and the lack of structured 
questionnaire for collection of symptoms and dietary adherence. Further, the median follow-up time 
in the study was too short to estimate long-term dietary adherence and the effects of an early-
initiated gluten-free diet on the possible complications and comorbidities of celiac disease.  
In conclusion, the high percentage of unrecognized clinical symptoms and excellent 
response and adherence to the gluten-free diet support active screening of celiac disease in at-risk 
children. An alternative option might be low-threshold case finding among at-risk children, but it is 
important to realize that even apparently asymptomatic patients may have well-advanced 
serological and histological disease and a subsequent risk of long-term complications. 
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Figure 1; online only. Presence (A) and severity (B) of clinical symptoms, degree of small-bowel 
mucosal villous atrophy (C) and adherence to the gluten-free diet (D) in 504 children diagnosed 
with celiac disease either by screening or upon clinical suspicion. Asymptomatic patients are 




















Figure 2. Transglutaminase 2 antibody values at the time of diagnosis and on a gluten-free diet in 







Figure 3; online only. Degree of small-bowel mucosal villous atrophy (A) and adherence to the 
gluten-free diet (B) in 139 screen-detected children with celiac disease divided into two groups 






Table 1. Demographic data and clinical characteristics in 504 children diagnosed with celiac disease by screening in at-risk groups or 
based on clinical suspicion. 
 Screen-detected (N = 145)  
Clinically detected 
(N = 359)  
 n %  n % P value3 
Age at diagnosis, median (Q1, Q3), yr 145 7.0 (4.1, 11.7)  359 8.0 (5.0, 11.7) 0.202 
Girls 90 62.1  239 66.6 0.336 
Celiac disease in the family 551 59.8  722 33.8 <0.001 
Type 1 diabetes 32 22.2  7 2.2 <0.001 
Thyroidal disease 2 1.4  5 1.6 1.000  
Down’s syndrome 0 0.0  4 1.3 0.314 
Anemia at diagnosis 10 7.1  72 22.9 <0.001 
Poor growth at diagnosis 22 15.7  117 36.9 <0.001 
Data available > 85% of the patients, except in 192 and 2213.  
3Chi-square test, Fisher’s exact test and Mann-Whitney U test. 
Q1 and Q3, lower and upper quartiles. 
 Table 2; online only. Distribution of symptoms at diagnosis in 398 screen-detected and clinically detected children with celiac disease. 
 Screen-detected (N = 72)  
Clinically detected 
(N = 326)  
 n1 %  n1 % P value2 
Stomach pain 61 55.7  295 65.4 0.152 
Diarrhea or loose stools 63 28.6  277 42.2 0.045 
Constipation 62 25.8  272 21.3 0.443 
Skin symptoms 72 9.7  325 6.2 0.300 
Arthralgia 72 2.8  326 7.7 0.194 
1Data available.  
2Chi-square and Fisher’s exact test. 
  
 
Table 3. Laboratory values and growth parameters at celiac disease diagnosis in 504 children diagnosed by screening in at-risk groups 
or based on clinical suspicion. 
 Screen-detected (N = 145)  
Clinically detected 
(N = 359)  
 n1 Median (Q1, Q3)  n1 Median (Q1, Q3) P value2 
Endomysial antibody, titer 103 1:500 (1:100, 1:2000)  247 1:500 (1:100, 1:1000) 0.576 
Hemoglobin, g/l 81 126 (121, 135)  258 124 (112, 131) 0.008 
Mean corpuscular volume, fl 67 81.0 (76.0, 84.0)  227 80.5 (76.0, 83.0) 0.595 
Albumin, g/l 19 41.0 (38.0, 42.0)  74 38.0 (36.8, 40.0) 0.016 
Transferrin receptor, mg/l 18 4.5 (3.1, 6.1)  67 4.4 (3.5, 6.5) 0.763 
Ferritin, µg/l 25 10.0 (6.0, 17.0)  83 13.0 (7.0, 23.0) 0.468 
Alanine aminotransferase, U/l 25 20.0 (16.0, 25.5)  122 20.0 (16.0, 26.0) 0.903 
Thyroid-stimulating hormone, mU/l 41 2.0 (1.5, 3.2)  120 2.5 (1.7, 3.3) 0.212 
Height, SD 87 0.3 (-0.5, 1.2)  170 0.0 (-0.8, 0.9) 0.242 
Weight, SD 66 -0.4 (-1.0, 0.5)  133 -0.3 (-1.3, 0.5) 0.695 
Body mass index, kg/m2 80 16.3 (15.0, 18.0)  167 16.3 (14.9, 18.6) 0.808 
1Data available.  
2Mann-Whitney U test. 
Q1 and Q3, lower and upper quartiles; SD, standard deviation. 
  
Table 4. Clinical characteristics, laboratory values and growth parameters in 139 children with screen-detected celiac disease divided 
into two groups based on the presence or absence of symptoms at diagnosis. 
 Asymptomatic screen-detected (N = 67)  
Symptomatic screen-detected 
(N = 72)  
 n %  n % P value4 
Girls 42 62.7  45 62.5 0.982 
Celiac disease in the family 231 54.8  312 68.9 0.175 
Type 1 diabetes 18 26.9  11 15.5 0.101 
Anemia at diagnosis 3 4.7  4 5.6 1.000 
Poor growth at diagnosis 11 16.9  9 12.9 0.506 
 n3 Median (Q1, Q3)  n3 Median (Q1, Q3)  
Age at diagnosis, yr 67 9.0 (4.9, 12.0)  72 5.8 (3.9, 10.0) 0.007 
Endomysial antibody, titer 53 1:200 (1:100, 1:1000)  45 1:1000 (1:200, 1:4000) 0.0325 
Hemoglobin, g/l 36 132 (123, 136)  39 124 (117, 130) 0.0106 
Height, SD 43 0.3 (-0.7, 1.2)  39 0.2 (-0.4, 1.2) 0.838 
Weight, SD 33 -0.5 (-1.1, 0.9)  29 -0.3 (-1.1, 0.3) 0.651 
Body mass index, kg/m2 43 16.0 (15.1, 18.1)  33 16.4 (14.8, 17.8) 0.604 
Data available > 95% of the patients, except in 142, 245 and 3numbers reported in the column below. 
4Chi-square test, Fisher’s exact test and Mann-Whitney U test. 
P values when adjusted for age using binary logistic regression: 50.076 and 60.233. 
Q1 and Q3, lower and upper quartiles; SD, standard deviation. 
